AbbVie Inc. $ABBV Shares Sold by Flagship Wealth Advisors LLC

Flagship Wealth Advisors LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 43.1% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 2,844 shares of the company’s stock after selling 2,153 shares during the quarter. Flagship Wealth Advisors LLC’s holdings in AbbVie were worth $619,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Foguth Wealth Management LLC. purchased a new stake in AbbVie during the first quarter worth approximately $368,000. Financial Solutions Advisory Group Inc. purchased a new position in shares of AbbVie in the 1st quarter valued at $2,123,000. Dala Group LLC acquired a new position in shares of AbbVie during the 1st quarter valued at $297,000. Blue Fin Capital Inc. boosted its position in AbbVie by 0.9% during the 1st quarter. Blue Fin Capital Inc. now owns 16,445 shares of the company’s stock worth $3,577,000 after purchasing an additional 147 shares during the period. Finally, Alpine Woods Capital Investors LLC boosted its position in AbbVie by 7.5% during the 1st quarter. Alpine Woods Capital Investors LLC now owns 31,234 shares of the company’s stock worth $6,793,000 after purchasing an additional 2,190 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of AbbVie stock opened at $251.33 on Friday. AbbVie Inc. has a 1-year low of $187.62 and a 1-year high of $267.47. The company has a market capitalization of $444.05 billion, a PE ratio of 71.00, a P/E/G ratio of 0.83 and a beta of 0.30. The business has a 50-day moving average of $239.10 and a 200-day moving average of $224.05.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. The company’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts expect that AbbVie Inc. will post 14.12 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research reports. Canaccord Genuity Group raised their price objective on AbbVie from $273.00 to $282.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. UBS Group raised their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Barclays upped their price target on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Wells Fargo & Company increased their price objective on shares of AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $269.29.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.